EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Evaluating the effectiveness of the eHealth-faciLitated SMILe–integrated care model on treatment burden, quality of life and graft-versus-host disease after allogeneic stem cell transplantation: results of two European randomized controlled implementation studies

Evaluierung der Wirksamkeit des eHealth-gestützten SMILe–integrated care model auf Behandlungsbelastung, Lebensqualität und Graft-versus-Host-Erkrankung nach allogener Stammzelltransplantation: Ergebnisse von 2 europäischen randomisierten kontrollierten Implementierungsstudien

Lynn Leppla, Sabine Valenta, Kris Denhaerynck, Anja Schmid, Janette Ribaut, Alexandra Teynor, Thomas Meyer, Claudia Wehr, Robert Zeiser, Sabine Gerull, Jörg Halter, Jakob Passweg und 1 weitere

Annals of Hematology · 24.10.2026 · 105 (11)

DOI: 10.1007/s00277-026-07333-1 ↗

Auf einen Blick

In 2 RCTs mit 152 Patient:innen war die Behandlungsbelastung unter SMILe–ICM geringer. Die gesundheitsbezogene Lebensqualität verbesserte sich in beiden Gruppen ohne Gruppenunterschied; akute GvHD trat seltener auf.

Fragestellung

Wie wirkt sich das SMILe–ICM nach allogener Stammzelltransplantation auf Behandlungsbelastung, Lebensqualität und GvHD aus?

Methode

Analyse von Daten aus 2 Hybrid-Effektivitäts-Implementierungs-RCTs an 2 europäischen Zentren; Erwachsene nach alloSCT 1:1 zu Standardversorgung oder SMILe–ICM; Intention-to-treat.

Ergebnisse

152 Patient:innen (76 SMILe–ICM, 76 Standardversorgung). Behandlungsbelastung niedriger im SMILe–ICM, mit signifikanten Unterschieden in 5 Dimensionen. Akute GvHD: 34,2 % vs. 55,3 %; HR 0,54 (95 %-KI 0,33–0,88; p = 0,01). Chronische GvHD: p = 0,64.

Schlussfolgerung der Autor:innen

SMILe–ICM verringerte die Behandlungsbelastung und war mit einer niedrigeren kumulativen Inzidenz von akuter GvHD Grad II–IV assoziiert; HRQoL und chronische GvHD unterschieden sich nicht signifikant.

Kernaussagen

  • Behandlungsbelastung unter SMILe–ICM geringer
  • Akute GvHD: 34,2 % vs. 55,3 %; HR 0,54
  • HRQoL und chronische GvHD ohne signifikante Unterschiede

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Hematology, online erschienen am 24.10.2026. Verfasst von Lynn Leppla und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. lynn.leppla@uniklinik-freiburg.de. Hauptthemen laut MEDLINE: Graft vs Host Disease, Quality of Life, Telemedicine, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Freiburg.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SMILe Integrated Care Model (SMILe–ICM) has previously demonstrated feasibility, successful implementation, and promising effects on survival, re-hospitalization, and cost-effectiveness following allogeneic stem cell transplantation (alloSCT). To complement these findings and provide a more comprehensive evaluation of the intervention’s effects, we evaluated patient-reported and clinical secondary outcomes from two RCTs. Data from two hybrid effectiveness-implementation RCTs conducted at two European alloSCT centers (Germany, Switzerland) were analyzed. Adult alloSCT recipients were randomized 1:1 to usual care (UCG) or the SMILe–ICM, a multicomponent intervention combining eHealth with advanced practice nurse-led self-management support. Treatment burden was assessed using the Patients’ Experience of Treatment and Self-Management (PETS 2.0), HRQoL using the EQ-5D-5 L, and GvHD outcomes using EBMT-registry data. Analyses followed an intention-to-treat approach. The current study examined data from 152 patients (76 SMILe–ICM, 76 UCG). Treatment burden was lower in the SMILe–ICM group, with significant differences in five dimensions. Both groups’ HRQoL improved over time without significant between-group differences. The cumulative incidence of acute GvHD was lower in the SMILe–ICM group than in the UCG (34.2% vs. 55.3%; HR 0.54, 95% CI 0.33–0.88; p = 0.01); chronic GvHD did not differ significantly ( p = 0.64). SMILe–ICM reduced treatment burden and was associated with a lower cumulative incidence of grades II–IV acute GvHD, while HRQoL and chronic GvHD did not differ significantly between groups. The acute GvHD finding warrants further investigation to determine whether and through which pathways integrated APN-led survivorship care may influence post-alloSCT clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseQuality of LifeTelemedicineHematopoietic Stem Cell TransplantationDelivery of Health Care, IntegratedHumansFemaleMiddle AgedAdultMaleTransplantation, HomologousSwitzerlandAgedGermanyDigital HealthCost of IllnessTreatment Outcome

Stichwörter der Autor:innen

Allogeneic stem cell transplantationGraft-versus-host diseaseHybrid effectiveness-implementation studyIntegrated care modelQuality of lifeeHealth

Autor:innen und Institutionen

  • Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. lynn.leppla@uniklinik-freiburg.de.
  • Department of Nursing, Medical Center, University of Freiburg, Freiburg, Germany. lynn.leppla@uniklinik-freiburg.de.
  • Institute of Nursing Science, Department Public Health, University of Basel, Basel, Switzerland.
  • Nursing Science, Institute of Health Sciences, Medical Faculty, University of Tübingen, Tübingen, Germany.
  • Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Nursing, Medical Center, University of Freiburg, Freiburg, Germany.

Förderung

  • Universitätsklinikum Freiburg

Zitieren

APA

Leppla, L., Valenta, S., Denhaerynck, K., Schmid, A., Ribaut, J., Teynor, A., Meyer, T., Wehr, C., Zeiser, R., Gerull, S., Halter, J., Passweg, J., & De Geest, S. (2026). Evaluating the effectiveness of the eHealth-faciLitated SMILe–integrated care model on treatment burden, quality of life and graft-versus-host disease after allogeneic stem cell transplantation: results of two European randomized controlled implementation studies. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07333-1

Vancouver

Leppla L, Valenta S, Denhaerynck K, Schmid A, Ribaut J, Teynor A, et al. Evaluating the effectiveness of the eHealth-faciLitated SMILe–integrated care model on treatment burden, quality of life and graft-versus-host disease after allogeneic stem cell transplantation: results of two European randomized controlled implementation studies. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07333-1

BibTeX
@article{Leppla2026,
  author = {Leppla, Lynn and Valenta, Sabine and Denhaerynck, Kris and Schmid, Anja and Ribaut, Janette and Teynor, Alexandra and Meyer, Thomas and Wehr, Claudia and Zeiser, Robert and Gerull, Sabine and Halter, Jörg and Passweg, Jakob and De Geest, Sabina},
  title = {Evaluating the effectiveness of the eHealth-faciLitated SMILe–integrated care model on treatment burden, quality of life and graft-versus-host disease after allogeneic stem cell transplantation: results of two European randomized controlled implementation studies},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07333-1}
}
Kostenlos starten →